Qingdao Wanming Cyber ​​Biopharmaceutical Co., Ltd.

Primary objective To evaluate the local (ocular) and systemic safety and tolerability of G01 eye drops after single/multiple ocular administration in healthy subjects; Secondary objective To evaluate the detectable blood drug concentration after single/multiple ocular administration of G01 eye drops in healthy subjects; if sufficient systemic exposure is detected, evaluate the pharmacokinetic (PK) characteristics of different concentrations of G01 eye drops in healthy adult subjects; Evaluate the immunogenicity of G01 eye drops after single/multiple ocular administration in healthy adult subjects.